RxDoctor Payments Data

An Tran, MD

Internal Medicine · Mount Vernon, NYNPI 1629454699

Payments from drug & device makers

$3,129in general payments, 2019–2025

Across 92 payments — averaging $34.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$414
  • Bayer$402
  • AstraZeneca$389
  • Novo Nordisk$323
  • AbbVie$310
  • Gilead$302
  • plus $989 from 16 others

What the payments were for

  • Food & beverage$3,129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,129 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$72,967
Medicare patients
171
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$84,910
EliquisApixaban40$65,119
OzempicSemaglutide32$45,778
VascepaIcosapent Ethyl38$35,014
TrulicityDulaglutide15$24,396
ProliaDenosumab13$23,437
JanuviaSitagliptin Phosphate17$22,403
KerendiaFinerenone16$18,754
XareltoRivaroxaban11$17,395
FarxigaDapagliflozin Propanediol11$16,148
LinzessLinaclotide14$15,615
Lidocaine114$13,452
TradjentaLinagliptin13$9,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,556
Diclofenac Sodium158$7,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$199$94,39772 claims
PfizerEliquis$43$65,11940 claims
Novo NordiskOzempic$323$45,77832 claims
Lilly USA, LLCTrulicity$86$24,39615 claims
AmgenProlia$414$23,43713 claims
MerckJanuvia$132$22,40317 claims
BayerKerendia$402$18,75416 claims
AstraZenecaFarxiga$389$16,14811 claims
AbbVieLinzess$310$15,61514 claims
GSKTrelegy Ellipta$164$8,55613 claims
ANI Pharmaceuticals, Inc.Valsartan$38$1,59181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →